Simris Biologics names ADC expert Andreas Pahl as CEO

• Simris Group appointed Professor Andreas Pahl as CEO of wholly owned Simris Biologics, effective immediately.
• Simris Biologics develops nature-derived antibody-drug conjugate payloads; Pahl will lead the Microcystin platform and shape future programs.
• Warrant exercise announced July 6, 2026 could raise up to EUR 1 million gross to fund Microcystin-ADC in vivo safety and efficacy studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simris Group AB published the original content used to generate this news brief on July 15, 2026, and is solely responsible for the information contained therein.